 |
|
|
|
|
 |
Last Updated: Sep 8, 2007 - 1:21:03 PM |
Latest Research
:
Pharmacology
:
Anticholesterol
:
Torceptrapib
ILLUMINATE study: Pfizer Stops All Torcetrapib Clinical Trials
FDA was notified that Pfizer will suspend a large, Phase 3 trial evaluating the investigational cardiovascular therapy torceptrapib/atorvastatin (T/A) due to an increased rate of mortality (death) in patients receiving the combination compared to those receiving atorvastatin alone. With the T/A development program, as it does with all such development programs, FDA assured that Pfizer had the appropriate protections in place for patients participating in the drug’s development, including informed consent, a Data Safety Monitoring Board (DSMB) for its outcome study, and that the development program was done in a careful, stepwise manner.
Dec 3, 2006 - 5:48:26 PM
|
Latest Research
:
Pharmacology
:
Anticholesterol
:
Torceptrapib
New Torcetrapib/Atorvastatin Research Further Supports Raising "Good" HDL Cholesterol
Pfizer said today that new data, involving its medicine in development torcetrapib/atorvastatin, provides important information on the benefit of raising HDL, or "good" cholesterol, while simultaneously lowering LDL, or "bad" cholesterol. These new findings may play a critical role in reducing the burden of cardiovascular disease and potentially improving quality of life for patients.
Mar 15, 2006 - 5:58:45 PM
|
Latest Research
:
Pharmacology
:
Anticholesterol
:
Torceptrapib
Study pinpoints protein inhibitor that raises HDL levels
An important clinical advance in the prevention of heart disease has been identified by researchers at the University of Pennsylvania School of Medicine, in collaboration with researchers at Tufts University and Pfizer. The study led by Daniel Rader, MD, Associate Professor of Medicine and Director of Penn's Preventive Cardiovascular Medicine & Lipid Center, involved a novel pharmacologic approach – inhibition of the cholesteryl ester transfer protein (CETP) – and showed that this approach is highly effective in raising high-density lipoprotein (HDL) levels in patients with low levels.
Apr 9, 2004 - 5:54:49 PM
|
<< prev
next >>
|
|
|
|
